Literature DB >> 17869513

Imidazopiperidine amides as dipeptidyl peptidase IV inhibitors for the treatment of diabetes.

Ping Chen1, Charles G Caldwell, Robert J Mathvink, Barbara Leiting, Frank Marsilio, Reshma A Patel, Joseph K Wu, Huaibing He, Kathryn A Lyons, Nancy A Thornberry, Ann E Weber.   

Abstract

A series of substituted imidazopiperidine amides has been prepared and evaluated for inhibition of dipeptidyl peptidase IV (DPP-4). Substitution at the 1- and 3-positions produced increased selectivity for DPP-4 relative to DPP-8 and DPP-9. Compounds in this series had IC(50) values as low as 5.8 nM for inhibition of DPP-4.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17869513     DOI: 10.1016/j.bmcl.2007.08.030

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  4 in total

1.  Synthesis, SAR, and Pharmacological Characterization of Brain Penetrant P2X7 Receptor Antagonists.

Authors:  Brad M Savall; Duncan Wu; Meri De Angelis; Nicholas I Carruthers; Hong Ao; Qi Wang; Brian Lord; Anindya Bhattacharya; Michael A Letavic
Journal:  ACS Med Chem Lett       Date:  2015-04-24       Impact factor: 4.345

2.  Identification of diverse dipeptidyl peptidase IV inhibitors via structure-based virtual screening.

Authors:  Cui Li; Weiqiang Lu; Chunhua Lu; Wen Xiao; Xu Shen; Jin Huang; Guixia Liu; Yun Tang
Journal:  J Mol Model       Date:  2012-03-30       Impact factor: 1.810

3.  Molecular docking and 3D-QSAR studies on beta-phenylalanine derivatives as dipeptidyl peptidase IV inhibitors.

Authors:  Yan-Ke Jiang
Journal:  J Mol Model       Date:  2010-01-13       Impact factor: 1.810

4.  Modified human glucagon-like peptide-1 (GLP-1) produced in E. coli has a long-acting therapeutic effect in type 2 diabetic mice.

Authors:  Fangfang Xu; Kevin Yueju Wang; Nan Wang; Gangqiang Li; Dehu Liu
Journal:  PLoS One       Date:  2017-07-27       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.